Minocycline prevents and repairs the skin disorder associated with afatinib one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer

摘要

Effects of minocycline WP on rash induced by afatinib ointment application. Left side is the TEWL value of control mice with low concentration (0.075%) afatinib WP for 7 days with/without minocycline WP treatment. Right side is high concentration (0.10%) afatinib WP treatment. Representative images of the effects of treatment with minocycline WP after onset of the rash. Left side is low concentration (0.075%) afatinib WP, and right side is treatment with minocycline WP from 7 days after the start of administration. Data (mean ± SD,  = 4 per group) are compared by one-way analysis of variance